10344 studies found for:    NCI
Show Display Options
Rank Status Study
1 Terminated SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Intervention: Drug: SJG-136
2 Terminated
Has Results
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Biological: cetuximab;   Biological: bevacizumab
3 Completed Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin;   Biological: fowlpox virus vaccine vector;   Biological: gp100 antigen
4 Active, not recruiting Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Condition: Malignant Neoplasm
Interventions: Drug: cixutumumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Completed Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
Conditions: L1 Childhood Acute Lymphoblastic Leukemia;   L2 Childhood Acute Lymphoblastic Leukemia;   Non-T, Non-B Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: cytarabine;   Drug: methotrexate;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: pegaspargase;   Drug: doxorubicin hydrochloride;   Drug: imatinib mesylate;   Drug: cyclophosphamide;   Drug: etoposide;   Biological: filgrastim;   Drug: leucovorin calcium;   Drug: asparaginase;   Drug: therapeutic hydrocortisone
6 Terminated Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection
Conditions: Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Procedure: therapeutic endoscopic surgery;   Other: laboratory biomarker analysis
7 Completed
Has Results
Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer
Conditions: Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: carboxyamidotriazole;   Other: placebo;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
8 Completed A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis
9 Completed UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: resveratrol
10 Completed Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage III Colon Cancer;   Stage III Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: sorafenib tosylate;   Drug: cetuximab;   Drug: irinotecan hydrochloride
11 Suspended Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Conditions: Adult Angiosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: trebananib;   Other: laboratory biomarker analysis
12 Completed Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
Conditions: Malignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
13 Recruiting Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
Conditions: Untreated Childhood Medulloblastoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: vorinostat;   Drug: isotretinoin;   Drug: vincristine sulfate;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: thiotepa;   Procedure: peripheral blood stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy;   Other: laboratory biomarker analysis
14 Active, not recruiting Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Richter Syndrome;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: lenalidomide;   Other: pharmacological study;   Other: laboratory biomarker analysis
15 Recruiting Entinostat and Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: entinostat;   Biological: aldesleukin;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography
16 Completed Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma
Conditions: Ovarian Cancer;   Sarcoma
Intervention: Drug: dolastatin 10
17 Active, not recruiting Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Drug: vorinostat;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis
18 Completed Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: bortezomib;   Drug: fluorouracil;   Drug: leucovorin calcium;   Other: pharmacological study;   Other: laboratory biomarker analysis
19 Completed Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: vorinostat;   Drug: paclitaxel;   Drug: carboplatin;   Other: placebo;   Other: laboratory biomarker analysis
20 Completed Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections
Conditions: Infection;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: recombinant interferon gamma;   Drug: voriconazole

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years